tiprankstipranks
Advertisement
Advertisement
GSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
PremiumRatingsGSK: Solid Quarter but Modest Outlook Prompts Hold Rating and Price Target Lift to £18.90
3d ago
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
Premium
Ratings
GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained
3d ago
GlaxoSmithKline Earnings Call Highlights Record Infrastructure
Premium
Company Announcements
GlaxoSmithKline Earnings Call Highlights Record Infrastructure
3d ago
GSK initiates ‘Accelerate Growth’ program
PremiumThe FlyGSK initiates ‘Accelerate Growth’ program
4d ago
GSK reports Q2 core EPS 50.5p, up 9% at CER
Premium
The Fly
GSK reports Q2 core EPS 50.5p, up 9% at CER
4d ago
GSK sees FY26 core EPS growth 7%-9%
Premium
The Fly
GSK sees FY26 core EPS growth 7%-9%
4d ago
GSK Canada announces approval of Shingrix in prefilled syringe
PremiumThe FlyGSK Canada announces approval of Shingrix in prefilled syringe
8d ago
GSK resumed with a Neutral at Citi
Premium
The Fly
GSK resumed with a Neutral at Citi
8d ago
GSK reports Jideytro approved by FDA for ROS1-positive NSCLC
Premium
The Fly
GSK reports Jideytro approved by FDA for ROS1-positive NSCLC
10d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100